How do I buy ACADIA Pharma (ACAD) stock?

Buying ACADIA Pharma (ACAD) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "ACAD", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy ACAD by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if ACAD is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

ACADIA Pharma (ACAD) Stock

Q: What is the minimum investment for ACAD on Gotrade?

On Gotrade , you don't have to buy a full lot. With fractional shares, you can start investing in ACADIA Pharma from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NSQ · ACAD

Trade ACAD

Key stats

Market cap: $3.54B
Price / Earnings ratio: 9.3x
EPS (TTM): $2.25
Volume: Loading
52-week high: $30.96
52-week low: $18.39
EPS vs analyst estimate: +85.7%Q3 FY25 · $0.26 vs $0.14

Source: third-party data provider, as of November 5, 2026

EPS estimate: analyst consensus

Compare with ACAD

Technical indicators

RSI 14: 54.46
MACD 12/26/9: -0.46
EMA 9 of MACD: -0.85
MACD histogram: 0.39
SMA 50: $23.20; Price below SMA 50
EMA 50: $22.26; Price below EMA 50
SMA 200: $23.60; Price below SMA 200
EMA 200: $23.66; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 4, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 9 analyst ratings

Strong Sell0

Sell0

Hold2

Buy7

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2022

2023

2025

1B849M424M0

Debt & Balance Sheet

Total assets

Total liabilities

2022

2023

2025

2B1B619M0

Revenue to Profit

2025

$1.1B

Revenue

$0.0

Cost of revenue

$982.5M

Gross profit

$0.0

Operating expenses

$391.0M

Net income

Earnings

EPS forecast

Actual EPS

$0.26

$0.14

Q3FY25

$0.15

Q4FY25

$0.13

Q1FY26

$0.20

Q2FY26

$0.22

Q3FY26

The market is expecting earnings per share of $0.22 for this quarter. The company has not yet shared when it is announcing earnings.

Source: third-party data provider

About ACADIA Pharma

Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.

SectorHealthcare

IndustryBiotechnology

Employees796

CEOMs. Catherine E. Owen Adams

IPO DateMay 27, 2004

HeadquartersSan Diego, CA

Key Executives

Name	Title	Year Born
Ms. Catherine E. Owen Adams	CEO & Director	1970
Mr. Mark C. Schneyer	Executive VP & CFO	1974
Ms. Jennifer J. Rhodes J.D.	Executive VP, Chief Legal Officer & Secretary	1970
Dr. Elizabeth H. Z. Thompson Ph.D.	Executive VP and Head of Research & Development	1976
Mr. Thomas Andrew Garner	Executive VP & Chief Commercial Officer	1976
Mr. Scott Cenci	Senior VP, Chief Information & Data Officer	—
Mr. Albert S. Kildani	Senior Vice President of Investor Relations & Corporate Communications	—
Mr. Carl Segerstrom	Chief People Officer	—
Mr. James K. Kihara	Senior Vice President of Finance	1981
Ms. Allyson McMillan-Youngblood	Senior Vice President of Rare Disease Franchise	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-1.9	+23.5
2022	-7.8	+6.6	-3.4	-27.9	-17.3	-13.9	+2.2	+16.4	-3.0	-5.9	-1.8	+3.8
2023	+16.6	+9.3	-10.0	+12.7	+8.0	+0.2	+21.8	-6.6	-25.0	+5.1	-2.8	+38.5
2024	-16.0	-11.1	-23.0	-8.5	-11.4	+6.3	+18.6	-12.7	-6.0	-4.6	+10.2	+10.5
2025	+0.0	+5.9	-8.5	-10.5	+48.0	+0.5	+11.6	+10.5	-16.9	+6.9	+11.9	+7.5
2026	-4.4	-6.0	-2.4	+0.6	-1.3	+17.6	+2.7	+12.9	-30.3	+3.5	+4.9

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

Agios Pharmaceuticals, Inc.

FAQ

Buying ACADIA Pharma (ACAD) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "ACAD", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy ACAD by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in ACADIA Pharma from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, ACADIA Pharma (ACAD) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track ACAD's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

ACADIA Pharma (ACAD) Stock

Key stats

Compare with ACAD

Recent news

Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026

Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026

Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline

Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline

Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026

Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026

Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026

Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline

Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline

Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026

Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?

4 CNS Drug Stocks Worth Watching This World Mental Health Day

4 CNS Drug Stocks Worth Watching This World Mental Health Day

Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041

Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal

ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal

ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets

ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets

ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20%

ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20%

About ACADIA Pharma

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade